Pancreatic Cancer Research

ResearcherNara Medical UniversityNo recent work listed

Naoya Ikeda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1498-8713; OpenAlex author ID A5029231452. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
29
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 4 papers · 2020: 1 paper · 2021: 2 papers

Papers 11

  1. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33284↗
  2. Clinical relevance of CD70 expression in resected pancreatic cancer: Prognostic value and therapeutic potential. Last author DOI 10.1016/j.pan.2021.01.013↗
  3. Three-dimensional remnant pancreatic volume ratio indicates postoperative pancreatic exocrine insufficiency in pancreatic cancer patients after distal pancreat… Co-author DOI 10.1016/j.pan.2020.06.018↗
  4. Risk Factors for Late-Onset Gastrointestinal Hemorrhage After Pancreatoduodenectomy for Pancreatic Cancer. Last author DOI 10.1007/s00268-018-4791-7↗
  5. A Comparison Between Plastic and Metallic Biliary Stent Placement in Patients Receiving Preoperative Neoadjuvant Chemoradiotherapy for Resectable Pancreatic Ca… Last author DOI 10.1007/s00268-018-4820-6↗
  6. Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. Last author DOI 10.1016/j.pan.2019.05.461↗
  7. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1634/theoncologist.2018-0900↗
  8. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-018-1709-7↗
  9. Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreati… Co-author DOI 10.1002/jhbp.318↗
  10. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic … Co-author DOI 10.1007/s00280-015-2928-z↗
  11. Potential role of surgical resection for pancreatic cancer in the very elderly. Co-author DOI 10.1016/j.pan.2015.03.015↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masayuki Sho · 10 shared papers, 2015–2021 · strength 0.81
  2. Takahiro Akahori · 10 shared papers, 2015–2021 · strength 0.81
  3. Minako Nagai · 10 shared papers, 2015–2021 · strength 0.81
  4. Satoshi Nishiwada · 9 shared papers, 2015–2021 · strength 0.72
  5. Kota Nakamura · 7 shared papers, 2018–2021 · strength 0.67
  6. Kenji Nakagawa · 7 shared papers, 2018–2021 · strength 0.67
  7. Kimihiko Kichikawa · 4 shared papers, 2018–2019 · strength 0.34
  8. Toshihiro Tanaka · 4 shared papers, 2018–2019 · strength 0.34
  9. Tadataka Takagi · 3 shared papers, 2019–2021 · strength 0.33
  10. So Yamaki · 4 shared papers, 2015–2019 · strength 0.23
  11. Hiroaki Yanagimoto · 4 shared papers, 2015–2019 · strength 0.23
  12. Sohei Satoi · 4 shared papers, 2015–2019 · strength 0.23
  13. Satoshi Hirooka · 4 shared papers, 2015–2019 · strength 0.23
  14. Tomohisa Yamamoto · 4 shared papers, 2015–2019 · strength 0.23
  15. Hideyuki Nishiofuku · 2 shared papers, 2019 · strength 0.18
  16. Chiho Ohbayashi · 2 shared papers, 2018–2019 · strength 0.16
  17. Tatsuya Oda · 1 shared paper, 2020 · strength 0.16
  18. Ryoichi Miyamoto · 1 shared paper, 2020 · strength 0.16
  19. Yoshiyuki Nakajima · 3 shared papers, 2015–2016 · strength 0.14
  20. Shoichi Kinoshita · 3 shared papers, 2015–2016 · strength 0.14
  21. Taichi Terai · 1 shared paper, 2021 · strength 0.13
  22. Wei Li · 1 shared paper, 2021 · strength 0.12
  23. Kensuke Yamamura · 1 shared paper, 2021 · strength 0.12
  24. Ajay Goel · 1 shared paper, 2021 · strength 0.12
  25. Hideo Baba · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.